SEARCH

SEARCH BY CITATION

References

  • Bauer, K.A., Humphries, S., Smillie, B., Li, L., Cooper, J.A., Barzegar, S., Rosenberg, R.D. & Miller, G.J. (2000) Prothrombin activation is increased among asymptomatic carriers of the prothrombin G20210A and factor V Arg506Gln mutations. Thrombosis and Haemostasis, 84, 396400.
  • Bloemenkamp, K.W., Rosendaal, F.R., Helmerhorst, F.M., Buller, H.R. & Vandenbroucke, J.P. (1995) Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen. Lancet, 346, 15931596.
  • Haim, N., Lanir, N., Hoffman, R., Haim, A., Tsalik, M. & Brenner, B. (2001) Acquired activated protein C resistance is common in cancer patients and is associated with venous thromboembolism. American Journal of Medicine, 110, 9196.
  • Mandala, M., Curigliano, G., Bucciarelli, P., Ferretti, G., Mannucci, P.M., Colleoni, M., Ventura, A., Peruzzotti, G., Severi, G., Pelicci, P.G., Biffi, R., Orsi, F., Cinieri, S. & Goldhirsch, A. (2004) Factor V Leiden and G20210A prothrombin mutation and the risk of subclavian vein thrombosis in patients with breast cancer and a central venous catheter. Annals of Oncology, 15, 590593.
  • Otterson, G.A., Monahan, B.P., Harold, N., Steinberg, S.M., Frame, J.N. & Kaye, F.J. (1996) Clinical significance of the FV:Q506 mutation in unselected oncology patients. American Journal of Medicine, 101, 406412.
  • Pihusch, R., Danzl, G., Scholz, M., Harich, D., Pihusch, M., Lohse, P. & Hiller, E. (2002) Impact of thrombophilic gene mutations on thrombosis risk in patients with gastrointestinal carcinoma. Cancer, 94, 31203126.
  • Poort, S.R., Rosendaal, F.R., Reitsma, P.H. & Bertina, R.M. (1996) A common genetic variant in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood, 88, 36983703.
  • Ramacciotti, E., Wolosker, N., Puech-Leao, P., Zeratti, E.A., Gusson, P.R., del Giglio, A. & Franco, R.F. (2003) Prevalence of factor V Leiden, FII G20210A, FXIII Val34Leu and MTHFR C677T polymorphisms in cancer patients with and without venous thrombosis. Thrombosis Research, 109, 171174.
  • Ranade, K., Chang, M.S., Ting, C.T., Pei, D., Hsiao, C.F., Olivier, M., Pesich, R., Hebert, J., Chen, Y.D., Dzau, V.J., Curb, D., Olshen, R., Risch, N., Cox, D.R. & Botstein, D. (2001) High-throughput genotyping with single nucleotide polymorphisms. Genome Research, 11, 12621268.
  • Ravin, A.J., Edwards, R.P., Krohn, M.A., Kelley, J.R., Christopherson, W.A. & Roberts, J.M. (2002) The factor V leiden mutation and the risk of venous thromboembolism in gynecologic oncology patients. Obstetrics and Gynecology, 100, 12851289.
  • Sifontes, M.T., Nuss, R., Hunger, S.P., Wilimas, J., Jacobson, L.J. & Manco-Johnson, M.J. (1997) The factor V Leiden mutation in children with cancer and thrombosis. British Journal of Haematology, 96, 484489.